Global Search | Novartis Canada

Hide Filters

Showing 30 results

Media Release / Sep 21, 2022
Novartis and the pan-Canadian Pharmaceutical Alliance (pCPA) conclude negotiations for Luxturna®, a gene therapy for previously untreatable inherited vision loss¹
Luxturna® (voretigene neparvovec) is a one-time gene therapy that provides healthy copies of the RPE65 gene for retinal cells that are lacking the normally functioning gene1 Dorval, QC, September…
Media Release / Sep 07, 2022
Health Canada approves PLUVICTO™ as first targeted radioligand therapy for progressive PSMA positive metastatic castration-resistant prostate cancer
Novel mechanism of action of PLUVICTO™ binds to target PSMA-positive cancer cells, delivering radiation treatment directly to those cells and nearby cells1 Prostate cancer is the most diagnosed…
Media Release / Aug 31, 2022
Scemblix™, a first-in-class CML treatment with new mechanism of action approved in Canada
Scemblix provides a new option for chronic myeloid leukemia (CML) patients who have had two or more previous tyrosine kinase inhibitor (TKI) treatments1 New mechanism of action with Scemblix…
Media Release / Jun 09, 2022
Novartis Pro Portal reimagines knowledge exchange in patient care, with seamless collaboration between the pharmaceutical industry and physicians
The product of over 120 consultations with health care practitioners, the Novartis Pro Portal is a one-stop digital hub developed to provide tailored, real-time support in daily practice. Dorval…
Media Release / Jun 09, 2022
Health Canada approves PrTabrecta®: Targeted cancer therapy for locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC) harbouring mesenchymal-epithelial transition (MET) exon 14 skipping alterations
Newest treatment for lung cancer reinforces Novartis commitment to developing innovative therapies that improve outcomes for Canadians affected by advanced lung cancer Dorval, Quebec, June 8,…
Media Release / Apr 25, 2022
Ontario and Quebec become the first provinces to list Kesimpta® (ofatumumab) for the treatment of adults with relapsing remitting multiple sclerosis (RRMS)
Kesimpta® is the first and only B-cell therapy for RRMS that can be administered by patients in the safety and convenience of their home Kesimpta® delivers superior efficacy with a favourable…
Media Release / Dec 17, 2021
Beovu® (brolucizumab injection) now publicly reimbursed in Ontario and New Brunswick for the treatment of neovascular (wet) age-related macular degeneration
Beovu® is an anti-VEGF that offers the option for eligible patients to start on a three-month dosing interval immediately after the loading phase with no compromise in efficacy. 1,2 While wet age-…
Media Release / Oct 27, 2021
Novartis launches Not Another Minute to educate Canadians and take action to bend the curve of cardiovascular disease (CVD)
In Canada, cardiovascular disease accounted for more than 52,000 deaths annually between 2015 and 20191 Almost 80% of deaths from cardiovascular disease are preventable2. Novartis is joining…
Media Release / Oct 19, 2021
Novartis applauds Quebec, the first province to list Zolgensma® for the treatment of pediatric patients with spinal muscular atrophy (SMA)
Public reimbursement is effective October 20th and will apply for children with SMA following the recommendation from the Institut national d'excellence en santé et services sociaux Zolgensma is…
Media Release / Oct 14, 2021
New campaign highlights urgent need for action to address the growing crisis of preventable vision loss and blindness
This World Sight Day, Fighting Blindness Canada and the Canadian Council of the Blind have partnered with Novartis Canada to launch “All Eyes on You”, a campaign urging Canadians to lend their…

Related News & Media